Gains in Survival Following Small Pancreatic NET Surgery?

Published Date: 15 Apr 2023

According to a recent study, surgery did not benefit patients with tumors smaller than 1 cm but did improve overall survival for those with 1 to 2 cm tumors. Who can benefit from resection may become clearer as a result of the findings.

Read Full News

Latest News

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

FDA Expansion of Linaclotide for Children 2-5 Years With Functional Constipation Julie Khlevner, MD, AGAF

Khlevner, MD, discusses the expanded FDA approval of linaclotide for children aged ≥2 years with functional constipation.

Obefazimod Sustains Remission After Dose Reduction in UC Extension Trial Abigail Brooks, MA

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

The HCPFive: Top News for Healthcare Providers from the Week of 05/24 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

6 Gastroenterology Headlines You Missed in May 2026 Abigail Brooks, MA

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

Abdominal Pain and Bloating: When to Consider HAE, MCAS, and EGIDs Brian Lacy, MD, PhD

Gastroenterologist Brian Lacy, MD, PhD, discusses how to differentiate HAE, MCAS, and eosinophilic GI disorders in patients with unexplained abdominal pain and bloating.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Khlevner, MD, discusses the expanded FDA approval of linaclotide for children aged ≥2 years with functional constipation.

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

Gastroenterologist Brian Lacy, MD, PhD, discusses how to differentiate HAE, MCAS, and eosinophilic GI disorders in patients with unexplained abdominal pain and bloating.

News All Time

FDA Approves Freenome Blood Test for Colorectal Cancer Screening Alex Hillenbrand

FDA approves Freenome's SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults aged ≥45 years.

TL1A Antibody Duvakitug Boosts Clinical Remission in UC, Response in CD Abigail Brooks, MA

Newly published phase 2b RELIEVE UCCD data show strong 14-week results for duvakitug in ulcerative colitis and Crohn disease.

How a Physician With Crohn's Disease Approaches IBD Care Jordan Axelrad, MD, MPH

Jordan E. Axelrad, MD, MPH, on selecting first-line IBD therapy, treat-to-target monitoring, and how living with Crohn's shapes patient care.

ABTECT Part 2 Data: Obefazimod Sustains Remission in UC Remo Panaccione, MD, FRCPC

Remo Panaccione, MD, discusses ABTECT Part 2 data: about 37% of prior non-responders achieved remission, with no new safety signals.

Metabolic Dysfunction May Explain Sugar-Sweetened Beverage–Gastric Cancer Link, With Andrew Chan, MD, MPH Andrew Chan, MD, MPH

New findings link sugar-sweetened beverages, but not artificial sweeteners, to increased gastric cancer risk, possibly tied to metabolic dysfunction.

Sugar-Sweetened Beverages Associated With Increased Gastric Cancer Risk, With Andrew Chan, MD, MPH Andrew Chan, MD, MPH

2-decade cohort study of 112,284 participants finds sugar-sweetened beverage intake linked to gastric cancer risk, with no link for artificial sweeteners.

6 Gastroenterology Headlines You Missed in August 2026 Alex Hillenbrand

Gastroenterology in August 2026: RAS inhibitor approval for pancreatic cancer, ABTECT UC data, CRC screening mortality, and GI cancer risk.

TEV '408 Meets Primary Endpoint in Celiac Trial Alex Hillenbrand

The phase 2a study found TEV '408 significantly reduced intestinal damage and inflammation versus placebo at week 8

43% Lower Mortality Seen in Colorectal Screening Participants Johannes Blom, MD, PhD

Karolinska Institute's Johannes Blom, MD, PhD, explains why colorectal cancer screening's real-world mortality benefit has been underestimated.

FDA Approves First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer Alex Hillenbrand

Daraxonrasib (Rasonque) extended median survival to 13.2 months versus 6.7 months with chemotherapy in a phase 3 trial.

Comprehensive Disease Control Starts With Asking, With David T. Rubin, MD

Comprehensive Disease Control Starts With Asking, With David T. Rubin, MD

The HCPFive: Top News for Healthcare Providers from the Week of 09/06

The HCPFive: Top News for Healthcare Providers from the Week of 09/06

C Diff Resistance to Bacitracin Reveals Potential Drug Target

C Diff Resistance to Bacitracin Reveals Potential Drug Target

SPY003 Meets Primary Endpoint in Phase 2 Trial for Ulcerative Colitis

SPY003 Meets Primary Endpoint in Phase 2 Trial for Ulcerative Colitis

A Life-Threatening Problem Hidden Within a Hiatal Hernia

Condition resolved after clinicians used a novel oral combination

Cirrhosis-Flagging Tool Stands Out for Steatotic Liver Disease in Primary Care

— SAFE outdid other risk scores in predicting 10-year cirrhosis risk

Recommended News For You

What are the factors that cause oral mucositis to be severe after receiving radiation for head and neck cancer?

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Axatilimab Demonstrates Effectiveness in Refractory/Recurrent GVHD.

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

C/EBP? works in tandem with MYB to sustain AML cells' oncogenic program.

Hemihedral resection not necessary for neuroendocrine surgery after appendicitis

One possible target in acute myeloid leukemia is the reductive carboxylation of glutamine.

Recommended Articles For You

Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis 

Beyond Immunotherapy: Emerging Novel Treatments for Small Cell Lung Cancer 

Iron Metabolism and Inflammatory Disorders: Mechanisms, Clinical Implications, and Therapeutic Approaches 

Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Early Identification of Ovarian Cancer; Allergy Medicine for NSCLC? Unfavorable Development for Anti-TIGIT Medication?

2.

No Laughing Matter: Nitrous Oxide for Transrectal Prostate Biopsy.

3.

Biomarker panel offers hope for early pancreatic cancer detection

4.

Financial hardship common in patients with cancer

5.

New protocols, according to a study, allow many patients to safely return home one day after lung cancer surgery.

1.

What You Need To Know About Secondary Polycythemia: Treatment & Symptoms

2.

Emerging Methods in Hematology in Clinical Decision-Making

3.

Fatigue Rehabilitation in Blood Disorders

4.

Digital Morphology Libraries for Hematology Education: Transforming Diagnostic Training and Clinical Practice

5.

Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer 

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

2.

Early Cancer Detection Saves Lives

3.

The Role of Hemoglobin in Maintaining Healthy Oxygen Levels

4.

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

5.

A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot